Accesswire · 15 Sept 2026positive
Cosmos Health announced that its subsidiary Cana Laboratories secured new five-year contract manufacturing agreements with Target Pharma totaling approximately 5.2 million units, bringing Cana's orderbook to over 32.7 million units and adding cardiovascular and anti-infective coverage to its therapeutic categories.
Why it matters — The expanded agreements and growing orderbook signal increased long-term production visibility and recurring revenue potential for Cosmos Health's contract manufacturing business.
Accesswire · 14 Sept 2026positive
Cosmos Health announced it has engaged Prime Ledger to structure an asset-specific, non-dilutive tokenized financing backed by its intellectual property in CCX0722, an ingestible hydrogel-based medical device in development for weight management, with no issuance of common stock. The company noted its patents are advanced in the US, Europe, Australia and Canada, and cited projections for the global weight-management market.
Why it matters — A COSM watcher would care because this tokenized IP-backed, non-dilutive financing structure positions Cosmos Health among the earliest NASDAQ-listed healthcare companies pursuing such assets while avoiding equity dilution to shareholders.
Accesswire · 11 Sept 2026positive
Cosmos Health's wholly owned subsidiary, Cana Laboratories, secured a new five-year contract manufacturing agreement with Viofar for approximately 2.5 million units of the cardiovascular therapy ROSARTIA (500,000 units annually). The cumulative contract manufacturing orderbook has risen to more than 27.5 million units, up from over 25 million units reported in June 2026.
Why it matters — The new agreement expands Cana's manufacturing presence in statin-based lipid-lowering cardiovascular pharmaceuticals and strengthens recurring cash-flow visibility and long-term relationships with established pharmaceutical companies.
Accesswire · 9 Sept 2026positive
Cosmos Health announced the launch of C-ScrubVet, its veterinary antimicrobial cleanser for dogs, cats, horses, and large animals, and reported that first orders have been received with sales commencing in the United Kingdom. The company plans to expand to additional European markets from Q4 2026, with initial multichannel distribution focusing on e-commerce before expanding to pet store chains and veterinary clinics.
Why it matters — This marks the extension of the company's C-Scrub franchise into the veterinary market, opening a new revenue stream and broadening Cosmos Health's addressable market through its vertically integrated manufacturing operations.
GlobeNewsWire · 3 Sept 2026positive
Cosmos Health published a comprehensive corporate summary covering January 1 through August 31, 2026, highlighting three consecutive quarters of record revenue growth, from FY2025's $65.3M (+20%) to Q1 2026's $17.93M (+31%) and Q2 2026's $18.99M (+28.8%). The company reported an annualized adjusted run-rate exceeding $75M.
Why it matters — The sustained double-digit revenue growth across multiple consecutive quarters signals consistent operational momentum for Cosmos Health investors monitoring the company's performance.
